Pancreatic cancer cells treated with the SREBP1 siRNA and gemcitabine exhibited decreased levels of these stem cell markers compared with the cells treated with gemcitabine alone (Figure 4E). This evidence concerns the gene SREBF1 and familial pancreatic carcinoma.